Tirzepatide studies: 457 papers with results
Page 2 of 10
- Greater improvement in insulin sensitivity per unit weight loss associated with tirzepatide versus semaglutide: An exploratory analysis.
Mather KJ · Diabetes, obesity & metabolism · 2025
Randomized controlled trial · 4 results
- Time spent in glycaemic control with sustained body weight reduction with tirzepatide: A post hoc analysis of the SURPASS clinical trial programme.
Bergman BK · Diabetes, obesity & metabolism · 2025
Randomized controlled trial · 7 results
- Liver Fat Changes in Patients With Type 2 Diabetes by Presence of Genetic Hepatic Steatosis: A Post Hoc Analysis of SURPASS-3 MRI.
Cusi K · Liver international : official journal of the International Association for the Study of the Liver · 2026
Randomized controlled trial · 6 results
- Psychiatric Safety of Tirzepatide in People With Obesity and No Known Major Psychopathology: A Post Hoc Analysis of SURMOUNT.
Wadden TA · Obesity (Silver Spring, Md.) · 2026
Randomized controlled trial · 5 results
- Predictors of ≥15% Weight Reduction and Associated Changes in Cardiometabolic Risk Factors With Tirzepatide in Adults With Type 2 Diabetes in SURPASS 1-4.
Małecki MT · Diabetes care · 2023
Randomized controlled trial · 7 results
- Tirzepatide Treatment and Associated Changes in β-Cell Function and Insulin Sensitivity in People With Obesity or Overweight With Prediabetes or Normoglycemia: A Post Hoc Analysis From the SURMOUNT-1 Trial.
Mari A · Diabetes care · 2025
Randomized controlled trial · 5 results
- Analysis of Tirzepatide Acquisition Costs and Weight Reduction Outcomes in the United Kingdom: Insights from the SURMOUNT-1 Study.
Evans M · Advances in therapy · 2025
Randomized controlled trial · 11 results
- A Pharmacometric Method for Quantitative Determination of Improvement in Body Composition and Characterization of the Exposure-Response Relationship during Treatment of Obesity with Tirzepatide.
Chigutsa E · Clinical pharmacology and therapeutics · 2025
Randomized controlled trial · 5 results
- Tirzepatide and change in uric acid and its association with weight reduction: post hoc analyses of the SURMOUNT-1 randomised placebo-controlled trial.
Sattar N · Annals of the rheumatic diseases · 2026
Randomized controlled trial · 7 results
- Tirzepatide reduces the predicted risk of atherosclerotic cardiovascular disease and improves cardiometabolic risk factors in adults with obesity or overweight: SURMOUNT-1 post hoc analysis.
Hankosky ER · Diabetes, obesity & metabolism · 2024
Randomized controlled trial · 4 results
- Effects of tirzepatide versus insulin glargine on kidney outcomes in type 2 diabetes in the SURPASS-4 trial: post-hoc analysis of an open-label, randomised, phase 3 trial.
Heerspink HJL · The lancet. Diabetes & endocrinology · 2022
Randomized controlled trial · 4 results
- Tirzepatide Improved Markers of Islet Cell Function and Insulin Sensitivity in People With T2D (SURPASS-2).
Frias JP · The Journal of clinical endocrinology and metabolism · 2024
Randomized controlled trial · 10 results
- Efficacy of tirzepatide versus semaglutide in achieving therapeutic targets in type 2 diabetes: a post hoc analysis of the SURPASS-2 Trial.
Neves JS · Diabetologia · 2026
Randomized controlled trial · 13 results
- Improvements in Cardiometabolic Risk Factors by Weight Reduction: A Post Hoc Analysis of Adults With Obesity Randomly Assigned to Tirzepatide.
Linetzky B · Annals of internal medicine · 2025
Randomized controlled trial · 14 results
- Time to weight plateau with tirzepatide treatment in the SURMOUNT-1 and SURMOUNT-4 clinical trials.
Horn DB · Clinical obesity · 2025
Randomized controlled trial · 6 results
- Interplay of Chronic Kidney Disease and the Effects of Tirzepatide in Patients With Heart Failure, Preserved Ejection Fraction, and Obesity: The SUMMIT Trial.
Packer M · Journal of the American College of Cardiology · 2025
Randomized controlled trial · 8 results
- Tirzepatide Associated With Improved Health-Related Quality of Life in Adults With Obesity or Overweight in SURMOUNT-4.
Gibble TH · Obesity (Silver Spring, Md.) · 2025
Randomized controlled trial · 4 results
- Characterization of tirzepatide-treated patients achieving different glycemic control levels in SURPASS-AP-Combo.
Bao Y · Obesity (Silver Spring, Md.) · 2024
Randomized controlled trial · 12 results
- Tirzepatide and health-related quality of life in adults with obesity or overweight: Results from the SURMOUNT-3 phase 3 randomized trial.
Gibble TH · Diabetes, obesity & metabolism · 2025
Randomized controlled trial · 7 results
- Association of bodyweight loss with changes in lipids, blood pressure, and fasting serum glucose following tirzepatide treatment in Japanese participants with type 2 diabetes: A post hoc analysis of the SURPASS J-mono trial.
Mimura H · Journal of diabetes investigation · 2025
Randomized controlled trial · 13 results
- Weight Changes With Tirzepatide and Concomitant Weight-Inducing Medications: Post Hoc Analysis of Randomized Clinical Trials.
Galindo RJ · JAMA network open · 2026
Randomized controlled trial · 3 results
- Tirzepatide compared with semaglutide in obesity disease: a subpopulation analysis applying Japan Society for the Study of Obesity criteria in the global SURMOUNT-5 trial.
Kitamoto T · Current medical research and opinion · 2026
Randomized controlled trial · 7 results
- Insulin Sensitivity and Beta-Cell Function Following Tirzepatide in Japanese Patients with Type 2 Diabetes: A SURPASS J-mono Analysis.
Hamamoto Y · Diabetes therapy : research, treatment and education of diabetes and related disorders · 2025
Randomized controlled trial · 40 results
- Dual GIP and GLP-1 Receptor Agonist Tirzepatide Improves Beta-cell Function and Insulin Sensitivity in Type 2 Diabetes.
Thomas MK · The Journal of clinical endocrinology and metabolism · 2021
Randomized controlled trial · 6 results
- Cardiometabolic Parameter Change by Weight Regain on Tirzepatide Withdrawal in Adults With Obesity: A Post Hoc Analysis of the SURMOUNT-4 Trial.
Horn DB · JAMA internal medicine · 2026
Randomized controlled trial · 10 results
- Weight reduction over time in tirzepatide-treated participants by early weight loss response: Post hoc analysis in SURMOUNT-1.
Ard J · Diabetes, obesity & metabolism · 2025
Randomized controlled trial · 4 results
- Association of baseline characteristics with clinical outcomes of tirzepatide treatment in Japanese patients with obesity disease: A subgroup analysis of the SURMOUNT-J trial.
Yokote K · Diabetes, obesity & metabolism · 2026
Randomized controlled trial · 12 results
- Post hoc analysis of SURMOUNT-J: tirzepatide versus placebo and predicted 10-year cardiovascular disease risk in Japanese adults with obesity disease.
Node K · Current medical research and opinion · 2026
Randomized controlled trial · 4 results
- Association of tirzepatide with cardiometabolic benefits in Chinese adults: post hoc subgroup analysis of SURMOUNT-CN study.
Zhao L · Obesity (Silver Spring, Md.) · 2025
Randomized controlled trial · 6 results
- Tirzepatide Reduces Appetite, Energy Intake, and Fat Mass in People With Type 2 Diabetes.
Heise T · Diabetes care · 2023
Randomized controlled trial · 9 results
- Predicting 10-year risk of type 2 diabetes in Chinese people with overweight or obesity treated with Tirzepatide: Post hoc analysis of SURMOUNT-CN trial.
Zhao L · Diabetes, obesity & metabolism · 2025
Randomized controlled trial · 5 results
- Change in pharmacodynamic variables following once-weekly tirzepatide treatment versus dulaglutide in Japanese patients with type 2 diabetes (SURPASS J-mono substudy).
Yabe D · Diabetes, obesity & metabolism · 2023
Randomized controlled trial · 12 results
- A Phase 1 Multiple Dose Study of Tirzepatide in Chinese Patients with Type 2 Diabetes.
Feng P · Advances in therapy · 2023
Randomized controlled trial · 11 results
- Effects of Novel Dual GIP and GLP-1 Receptor Agonist Tirzepatide on Biomarkers of Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes.
Hartman ML · Diabetes care · 2020
Randomized controlled trial · 10 results
- The dual glucose-dependent insulinotropic peptide and glucagon-like peptide-1 receptor agonist, tirzepatide, improves lipoprotein biomarkers associated with insulin resistance and cardiovascular risk in patients with type 2 diabetes.
Wilson JM · Diabetes, obesity & metabolism · 2020
Randomized controlled trial · 21 results
- Tirzepatide did not impact metabolic adaptation in people with obesity, but increased fat oxidation.
Ravussin E · Cell metabolism · 2025
Randomized controlled trial · 6 results
- Tirzepatide Associated With Reduced Albuminuria in Participants With Type 2 Diabetes: Pooled Post Hoc Analysis From the Randomized Active- and Placebo-Controlled SURPASS-1-5 Clinical Trials.
Apperloo EM · Diabetes care · 2025
Randomized controlled trial · 7 results
- Association between weight reduction achieved with tirzepatide and quality of life in adults with obesity: Results from the SURMOUNT-1 study.
Gudzune KA · Diabetes, obesity & metabolism · 2025
Randomized controlled trial · 6 results
- Tirzepatide reduces the predicted risk of developing type 2 diabetes in people with obesity or overweight: Post hoc analysis of the SURMOUNT-1 trial.
Hankosky ER · Diabetes, obesity & metabolism · 2023
Randomized controlled trial · 8 results
- Gastrointestinal adverse events and weight reduction in people with type 2 diabetes treated with tirzepatide in the SURPASS clinical trials.
Patel H · Diabetes, obesity & metabolism · 2024
Randomized controlled trial · 10 results
- Tirzepatide and blood pressure reduction: stratified analyses of the SURMOUNT-1 randomised controlled trial.
Krumholz HM · Heart (British Cardiac Society) · 2024
Randomized controlled trial · 8 results
- Achievement of glycaemic targets with weight loss and without hypoglycaemia in type 2 diabetes with the once-weekly glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist tirzepatide: A post hoc analysis of the SURPASS-1 to -5 studies.
Lingvay I · Diabetes, obesity & metabolism · 2023
Randomized controlled trial · 7 results
- Effects of Tirzepatide vs Semaglutide on β-Cell Function, Insulin Sensitivity, and Glucose Control During a Meal Test.
Mather KJ · The Journal of clinical endocrinology and metabolism · 2024
Randomized controlled trial · 16 results
- Effect of tirzepatide treatment on patient-reported outcomes among SURMOUNT-OSA participants with obstructive sleep apnea and obesity.
Kanu C · Sleep medicine · 2025
Randomized controlled trial · 8 results
- Tirzepatide leads to weight reduction in people with obesity due to MC4R deficiency.
Bhatnagar P · Nature medicine · 2025
Randomized controlled trial · 3 results
- Gastrointestinal tolerability and weight reduction associated with tirzepatide in adults with obesity or overweight with and without type 2 diabetes in the SURMOUNT-1 to -4 trials.
Rubino DM · Diabetes, obesity & metabolism · 2025
Randomized controlled trial · 6 results
- Tirzepatide and the 10-year predicted risk of cardiovascular disease and type 2 diabetes in adults with obesity and prediabetes: A post hoc analysis from the three-year SURMOUNT-1 trial.
Hankosky ER · Diabetes, obesity & metabolism · 2025
Randomized controlled trial · 9 results
- Early-Onset Type 2 Diabetes and Tirzepatide Treatment: A Post Hoc Analysis From the SURPASS Clinical Trial Program.
Zeitler P · Diabetes care · 2024
Randomized controlled trial · 6 results
- Tirzepatide for sleep-disordered breathing in SURMOUNT-OSA: Time course and association with body weight.
Malhotra A · Sleep medicine · 2025
Randomized controlled trial · 6 results
- Improved health-related quality of life with tirzepatide versus semaglutide in adults with obesity or overweight from the SURMOUNT-5 trial.
Shukla AP · Diabetes, obesity & metabolism · 2026
Randomized controlled trial · 12 results